Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection

Κaur, Kirandeep; Kumar, Parveen; Kush, Preeti

doi:10.1016/j.biopha.2020.110297

Cited by 23 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These conditions allow the production of ethylcellulose NPs with 69 ± 2 nm and a PDI of 0.18 ± 0.04. The average size is lower than the ones presented elsewhere, for ethylcellulose NPs produced by nanoprecipitation (using acetone as solvent) [ 34 ] and high-pressure emulsification solvent evaporation [ 35 ], which obtained sizes of 163 nm and 150 nm, respectively; the same size range is obtained for NPs produced by electrospray [ 36 ] and nanoprecipitation (using ethanol as solvent) [ 37 ].…”

Section: Resultsmentioning

confidence: 52%

Bio-Based Nanoparticles as a Carrier of β-Carotene: Production, Characterisation and In Vitro Gastrointestinal Digestion

et al. 2020

View full text Add to dashboard Cite

β-carotene loaded bio-based nanoparticles (NPs) were produced by the solvent-displacement method using two polymers: zein and ethylcellulose. The production of NPs was optimised through an experimental design and characterised in terms of average size and polydispersity index. The processing conditions that allowed to obtain NPs (<100 nm) were used for β-carotene encapsulation. Then β-carotene loaded NPs were characterised in terms of zeta potential and encapsulation efficiency. Transmission electron microscopy, Fourier transform infrared spectroscopy and X-ray diffraction analysis were performed for further morphological and chemical characterisation. In the end, a static in vitro digestion following the INFOGEST protocol was performed and the bioaccessibility of β-carotene encapsulated in both NPs was determined. Results show that the best conditions for a size-controlled production with a narrow size distribution are lower polymer concentrations and higher antisolvent concentrations. The encapsulation of β-carotene in ethylcellulose NPs resulted in nanoparticles with a mean average size of 60 ± 9 nm and encapsulation efficiency of 74 ± 2%. β-carotene loaded zein-based NPs resulted in a mean size of 83 ± 8 nm and encapsulation efficiency of 93 ± 4%. Results obtained from the in vitro digestion showed that β-carotene bioaccessibility when encapsulated in zein NPs is 37 ± 1%, which is higher than the value of 8.3 ± 0.1% obtained for the ethylcellulose NPs.

show abstract

Section: Resultsmentioning

confidence: 52%

Bio-Based Nanoparticles as a Carrier of β-Carotene: Production, Characterisation and In Vitro Gastrointestinal Digestion

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The data are representative of several experiments performed in duplicate and expressed as the mean ± standard error, where (*) represent when P ≤ 0.05 loaded with β-cyclodextrin and five drugs (Quericitin, Ceftrixon, Naranjin, Amphotericin B and Ampicillin). These formulations were characterized using a range of techniques such as zeta potential analysis and zeta sizer, UV-visible, FTIR, AFM as previously described (Gagoś and Arczewska 2010;Ethiraj et al 2014;Catauro et al 2015;Liu et al 2015;Diaz-Uribe et al 2016;Kalaiselvi et al 2016;Kavitha et al 2017;Mushtaq et al 2017;Reddy et al 2020;Kadam et al 2020;Kaur et al 2020;Yang et al 2020;Sathishkumar et al 2021). ZnO-NPs were synthesized using direct precipitation method and upon successful formation coupled with β-cycldextrin.…”

Section: Discussionmentioning

confidence: 99%

Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules

et al. 2021

View full text Add to dashboard Cite

At present, antibiotic resistance is one of the most pressing issues in healthcare globally. The development of new medicine for clinical applications is significantly less than the emergence of multiple drug-resistant bacteria, thus modification of existing medicines is a useful avenue. Among several approaches, nanomedicine is considered of potential therapeutic value. Herein, we have synthesized Zinc oxide nanoparticles (ZnO-NPs) conjugated with clinically-approved drugs (Quercetin, Ceftriaxone, Ampicillin, Naringin and Amphotericin B) with the aim to evaluate their antibacterial activity against several Gram-positive (Methicillin resistant Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes) and Gram-negative (Escherichia coli K1, Serratia marcescens and Pseudomonas aeruginosa) bacteria. The nanoparticles and their drug conjugates were characterized using UV-visible spectrophotometry, dynamic light scattering, Fourier transform infrared spectroscopy and atomic force microscopy. Antibacterial activity was performed by dilution colony forming unit method and finally 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed to determine their cytotoxic effects against human cell lines. ZnO-NPs revealed maxima surface plasmon resonance band at 374 and after conjugation with beta-cyclodextrin at 379 nm, polydispersity with size in range of 25–45 nm with pointed shaped morphology. When conjugated with ZnO-NPs, drug efficacy against MDR bacteria was enhanced significantly. In particular, Ceftriaxone- and Ampicillin-conjugated ZnO-NPs exhibited potent antibacterial effects. Conversely, ZnO-NPs and drugs conjugated NPs showed negligible cytotoxicity against human cell lines except Amphotericin B (57% host cell death) and Amphotericin B-conjugated with ZnO-NPs (37% host cell death). In conclusion, the results revealed that drugs loaded on ZnO-NPs offer a promising approach to combat increasingly resistant bacterial infections.

show abstract

“…Gadalla et al [ 169 ] used pectin-NaCMC microspheres to deliver progesterone to the colon, and found a 1.8-fold increase in AUC and 2.3-fold increase in mean residence time when compared to a free solution of progesterone. Kaur et al [ 170 ] developed EC nanoparticles for amphotericin B delivery for antifungal applications, and demonstrated a 15-fold improvement in oral bioavailability when compared to a free solution of amphotericin B.…”

Section: Mucoadhesive Drug Delivery Systemsmentioning

confidence: 99%

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

2022

View full text Add to dashboard Cite

Oral delivery of therapeutics is the preferred route of administration due to ease of administration which is associated with greater patient medication adherence. One major barrier to oral delivery and intestinal absorption is rapid clearance of the drug and the drug delivery system from the gastrointestinal (GI) tract. To address this issue, researchers have investigated using GI mucus to help maximize the pharmacokinetics of the therapeutic; while mucus can act as a barrier to effective oral delivery, it can also be used as an anchoring mechanism to improve intestinal residence. Nano-drug delivery systems that use materials which can interact with the mucus layers in the GI tract can enable longer residence time, improving the efficacy of oral drug delivery. This review examines the properties and function of mucus in the GI tract, as well as diseases that alter mucus. Three broad classes of mucus-interacting systems are discussed: mucoadhesive, mucus-penetrating, and mucolytic drug delivery systems. For each class of system, the basis for mucus interaction is presented, and examples of materials that inform the development of these systems are discussed and reviewed. Finally, a list of FDA-approved mucoadhesive, mucus-penetrating, and mucolytic drug delivery systems is reviewed. In summary, this review highlights the progress made in developing mucus-interacting systems, both at a research-scale and commercial-scale level, and describes the theoretical basis for each type of system.

show abstract

Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection

Cited by 23 publications

References 43 publications

Bio-Based Nanoparticles as a Carrier of β-Carotene: Production, Characterisation and In Vitro Gastrointestinal Digestion

Bio-Based Nanoparticles as a Carrier of β-Carotene: Production, Characterisation and In Vitro Gastrointestinal Digestion

Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules

Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems

Contact Info

Product

Resources

About